stockrow
Friday 6 November 2026
Export IRWD’s income statement to Excel — free account
Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024.
- Revenue
- +9.00%
- EPS
- +45.2%
- Free cash flow
- +41.7%
- Total debt
- −44.4%
Quarter to September 2026, against a year earlier
4.36
0.33
+8.19%
Follow IRWD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (82.81%) | (55.26%) | (37.07%) | (8.53%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 6 | 6 | 5 | |
| 43.58% | 41.35% | 26.83% | 6.42% | ||
ROIC |
111.28% | 101.61% | 84.97% | 57.33% | |
Return on Tangible Assets |
77.16% | 76.73% | 103.05% | 67.91% | |
Average Days of Receivables |
121.02 | 105.69 | 106.86 | 57.61 | |
Free Cash Flow per Share |
1.25 | 1.13 | 0.69 | 0.78 | |
Free Cash Flow |
205.37 | 185.56 | 112.21 | 127.01 | |
Capital Expenditures |
— | — | — | (0.03) | |
| Other line items | |||||
Cash ROIC |
65.37% | 61.38% | 19.08% | 23.59% | |
Accounts Receivable Turnover |
3.16 | 3.91 | 4.97 | 4.60 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.34) | (0.37) | (0.40) | (0.66) | |
Research and Development Expense of Revenue |
23.63% | 22.78% | 24.80% | 32.12% | |
Selling, General and Administrative Expense of Revenue |
13.54% | 16.58% | 19.37% | 27.78% | |
Share Based Compensation of Revenue |
3.75% | 3.68% | 4.32% | 5.82% | |
Interest Coverage |
8.28 | 7.17 | 5.92 | 3.01 | |
Operating CF/Net income |
1.37 | 1.43 | 1.10 | 5.29 | |
Depreciation/Fixed assets |
0.68 | 0.63 | 0.58 | 0.55 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.02) | |
Revenue per Share |
2.43 | 2.37 | 2.21 | 1.83 | |
Operating CF per Share |
1.25 | 1.13 | 0.69 | 0.79 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026